Publication:
Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors

dc.contributor.authorPerez-Sautu, Unai
dc.contributor.authorPozo Sanchez, Francisco
dc.contributor.authorCuesta de la Plaza, Isabel
dc.contributor.authorMonzon-Fernandez, Sara
dc.contributor.authorCalderon-Reñon, Ana Maria
dc.contributor.authorGonzalez, M
dc.contributor.authorMolinero, Mar
dc.contributor.authorLópez-Miragaya, Isabel
dc.contributor.authorRey, Sonia
dc.contributor.authorCañizares, A
dc.contributor.authorRodriguez, G
dc.contributor.authorGonzalez-Velasco, C
dc.contributor.authorLackenby, A
dc.contributor.authorCasas Flecha, Inmaculada
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderCentro de Investigación Biomedica en Red - CIBER
dc.date.accessioned2020-02-03T08:56:20Z
dc.date.available2020-02-03T08:56:20Z
dc.date.issued2014-07-10
dc.description.abstractThe Y155H amino acid substitution in the neuraminidase gene (NA) has previously been associated with highly reduced inhibition by neuraminidase inhibitors in the seasonal H1N1 influenza A virus which circulated in humans before the 2009 pandemic. During the 2012/13 epidemic season in Spain, two A(H1N1) pdm09 viruses bearing the specific Y155H substitution in the NA were detected and isolated from two patients diagnosed with severe respiratory syndrome and pneumonia requiring admission to the intensive care unit. Contrary to what was observed in the seasonal A(H1N1) viruses, neither of the Y155H A(H1N1) pdm09 viruses described here showed a phenotype of reduced inhibition by NAIs as determined by the neuraminidase enzyme inhibition assay (MUNANA). High-throughput sequencing of the NA of both Y155H viruses showed that they were composed to >99% of H155 variants. We believe that this report can contribute to a better understanding of the biological significance of amino acid substitutions in the neuraminidase protein with regard to susceptibility of influenza viruses to neuraminidase inhibitors. This is of critical importance for optimal management of influenza disease patients.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipWe would like to acknowledge Dr. Angel Zaballos Sanz at the Genomics Unit of the National Centre for Microbiology of the Carlos III Health Institute and the Next Generation Sequencing service at the Cantoblanco Genomics Unit of the Madrid Scientific Park for their support, and all the members of the Spanish Influenza Surveillance System working in the identification and declaration of patients during the 2012/13 influenza season. We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from GISAID EpiFlu Database which have been included in this research. This work was supported by Instituto de Salud Carlos III (Programa especial de investigación sobre la gripe pandémica) GR09/0040. Sara Monzon received a research contract funding by the Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER U758). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.es_ES
dc.format.number27es_ES
dc.format.page14-20es_ES
dc.format.volume19es_ES
dc.identifier.citationEuro Surveill. 2014 Jul 10;19(27):14-20.es_ES
dc.identifier.doi10.2807/1560-7917.ES2014.19.27.20849es_ES
dc.identifier.e-issn1560-7917es_ES
dc.identifier.journalEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletines_ES
dc.identifier.pubmedID25033052es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9001
dc.language.isoenges_ES
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/GR09/0040es_ES
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES2014.19.27.20849es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshAmino Acid Substitutiones_ES
dc.subject.meshAntiviral Agentses_ES
dc.subject.meshDrug Resistance, Virales_ES
dc.subject.meshEnzyme Inhibitorses_ES
dc.subject.meshFemalees_ES
dc.subject.meshHumanses_ES
dc.subject.meshImmunoenzyme Techniqueses_ES
dc.subject.meshInfluenza A Virus, H1N1 Subtypees_ES
dc.subject.meshInfluenza, Humanes_ES
dc.subject.meshMalees_ES
dc.subject.meshMicrobial Sensitivity Testses_ES
dc.subject.meshNeuraminidasees_ES
dc.subject.meshOseltamivires_ES
dc.subject.meshPandemicses_ES
dc.subject.meshPhenotypees_ES
dc.subject.meshRNA, Virales_ES
dc.subject.meshSeasonses_ES
dc.subject.meshSequence Analysis, DNAes_ES
dc.subject.meshSpaines_ES
dc.subject.meshViral Proteinses_ES
dc.subject.meshZanamivires_ES
dc.titleY155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitorses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication03c0b4b5-5fb2-4ff0-aa27-ca6fb37d5843
relation.isAuthorOfPublication5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isAuthorOfPublication649d9dae-bb8e-46b3-82f3-e9b14d2a3670
relation.isAuthorOfPublication7cffc9dc-bb9e-4d48-a041-5fb6013b1b65
relation.isAuthorOfPublicationb4c4b416-bc32-4da5-ae03-e4d222a8cbfe
relation.isAuthorOfPublicationb407bbd4-ab14-45f3-a7ab-105b40124fc1
relation.isAuthorOfPublicatione2df6e55-f1d3-423b-a72f-fd9a69cf5915
relation.isAuthorOfPublication.latestForDiscovery03c0b4b5-5fb2-4ff0-aa27-ca6fb37d5843
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication.latestForDiscovery7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Y155HAminoAcidSubstitution_2014.pdf
Size:
531.96 KB
Format:
Adobe Portable Document Format
Description: